A protein specialist that opens the genomic door for DNA repair and gene expression also turns out to be a multi-tasking workhorse that protects the tips of chromosomes and dabbles in a protein-destruction complex, a team lead by researchers at The University of Texas M. D. Anderson Cancer Center reports in the Aug. 13 edition of Molecular Cell.
EMD Serono, Inc. and The University of Texas M. D. Anderson Cancer Center today announced a strategic alliance designed to provide M. D. Anderson with early insight into potential cancer treatments and to accelerate EMD Serono's preclinical and early clinical research to ultimately bring new drugs to patients faster. The agreement is set for three years with the potential to renew the alliance. Both parties decided not to disclose financial details.
The Anderson Network at The University of Texas M. D. Anderson Cancer Center is delighted to welcome Hoda Kotb, co-anchor for the fourth hour of TODAY, a Dateline NBC correspondent and host of the weekly syndicated series "Your Total Health," as the keynote speaker for Anderson Network's 21st annual Living With, Through and Beyond Cancer conference Sept. 10-12.
The focus is usually on the patient - but often the patients' children are almost as affected by a diagnosis of cancer as the person undergoing treatment.
M. D. Anderson recommends healthy activities to reduce cancer risks.
A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3rd.
Researchers have pinpointed a specific gene variation that causes increased risk of urinary bladder cancer, according to a scientific team led by The University of Texas M. D. Anderson Cancer Center.
Taking the most commonly-prescribed anti-diabetic drug, metformin, reduces an individual's risk of developing pancreatic cancer by 62 percent, according to research from The University of Texas M. D. Anderson Cancer Center, published in the Aug. 1 issue of Gastroenterology.
With a novel therapeutic delivery system, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center has successfully targeted a protein that is over-expressed in ovarian cancer cells. Using the EphA2 protein as a molecular homing mechanism, chemotherapy was delivered in a highly selective manner in preclinical models of ovarian cancer, the researchers report in the July 29 issue of the Journal of the National Cancer Institute.
Expression of a single gene programs an immune system helper T cell that fuels rapid growth and diversification of antibodies in a cellular structure implicated in autoimmune diseases and development of B cell lymphoma, scientists at The University of Texas M. D. Anderson Cancer Center reported today in Science Express, the advance online publication of the journal Science.
Common genetic variations spread across five genes raise a person's risk of developing the most frequent type of brain tumor, an international research team reports online in Nature Genetics.
To help you better prepare for Independence Day, nutrition experts at The University of Texas M. D. Anderson Cancer Center offer advice on how to barbeque the healthy way. M. D. Anderson dietitian, Vicki Piper, R.D., L.D., encourages cookout fans to grill plenty of fruits and vegetables, and less meat. Diets high in plant foods can lower your chances of developing several cancers, including breast and colon cancers.
Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.
In reviewing the weight history of pancreatic cancer patients across their life spans, researchers at The University of Texas M. D. Anderson Cancer Center have determined that a high body mass index in early adulthood may play a significant role in an individual developing the disease at an earlier age.
Hoda Kotb, host of the weekly syndicated series "Your Total Health," and a breast cancer survivor, will be the keynote speaker for Anderson Network's 21st annual Living With, Through and Beyond Cancer conference Sept. 10-12, at the Houston Marriott Westchase.
Like a mechanic popping the hood of a car to get at a faulty engine, a tumor-suppressing protein allows cellular repair mechanisms to pounce on damaged DNA by overcoming a barrier to DNA access.
Four suspects often found at the scene of the crime in cancer are guilty of the initiation and progression of breast cancer in mice that are resistant to the disease, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the June edition of Cancer Cell.
The difficult journey of a cancer survivor can inspire couples to celebrate life. For some, however, cancer treatment's physical toll can interrupt this celebration, especially when it comes to intimacy. M. D. Anderson experts offer advice on intimacy to women and their lovers.
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.
A Dream Team of leading cancer researchers will accelerate development of drugs to attack a mutated molecular pathway that fuels endometrial, breast and ovarian cancers, funded by a three-year $15 million grant awarded today by Stand Up To Cancer.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
A Conversation With a Living Legend, an annual luncheon benefiting The University of Texas M. D. Anderson Cancer Center, will spotlight former First Lady and newly settled Dallas resident Mrs. Laura Bush in an exclusive interview Sept. 18 at the Hilton Anatole in Dallas. Event organizers hope this year's 20th anniversary event will hit the $10 million mark in total funds raised for research, patient care and educational initiatives at M. D. Anderson.
At some point during their care, more than one-third of metastatic breast cancer patients receive chemotherapy off label, the legal use of FDA-approved drugs in a different indication than for which they were approved, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Breast cancer patients who received chemotherapy prior to surgery had heightened levels of cancer-initiating stem cells in their bone marrow, and the level of such cells correlated to a tumor's lymph node involvement, according to research from The University of Texas M. D. Anderson Cancer Center.
A home-based program aimed at improving exercise and diet can lead to meaningful improvements in physical function among older long-term cancer survivors, according to the results of a study led by researchers from Duke University Medical Center and The University of Texas M. D. Anderson Cancer Center.
New book reveals the birth and rise of M. D. Anderson. Pulitzer-nominee James S. Olson brings a uniquely personal view to history.
Today Banner Health and The University of Texas M. D. Anderson Cancer Center announced they will create the M. D. Anderson Banner Cancer Center. The initiative joins Arizona's leading provider of health care and the nation's leading cancer center to provide patients and their families with an unprecedented level of cancer care in Arizona.
A newly discovered gene known as DEAR1 is mutated in breast cancer and is an independent predictor of local recurrence-free survival in early-onset breast cancer, a research team headed by scientists at The University of Texas M. D. Anderson Cancer Center reports in the journal PLoS Medicine.
May is Skin Cancer Awareness Month and The University of Texas M. D. Anderson Cancer Center now offers insight into how some of today's hottest fashion trends can offer a tremendous amount of sun protection without leaving you feeling like a well-greased baking pan.
Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45 percent, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly and minority populations, according to research from The University of Texas M. D. Anderson Cancer Center.
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer. The study was presented today at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO).
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells. The pre-clinical study was presented today in a platform session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO).
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a way to prevent blood vessels from aiding the growth of neuroblastoma, a childhood cancer. The pre-clinical study was presented today in a platform session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology.
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a new drug that restricts the growth of neuroblastoma, a childhood brain cancer. The pre-clinical study was presented today in the plenary session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology.
Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research.
Twice weekly acupuncture treatments relieve debilitating symptoms of xerostomia - severe dry mouth - among patients treated with radiation for head and neck cancer, researchers from The University of Texas M. D. Anderson Cancer Center report in the current online issue of Head & Neck.
Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle invasive bladder cancer (NMIBC) who are treated with mainstream therapy.
Genetic variations in the micro-RNA (miRNA) processing pathway genes and miRNA binding sites predict a woman's risk for developing ovarian cancer and her prospects for survival, researchers from The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research.
An inflammatory protein implicated in a variety of cancers is the target of the first joint symposium between the nation's two premier cancer research organizations.
Back when scientists viewed immune response as an either-or process strictly divided between two pathways, each driven by a separate T helper cell, Chen Dong, Ph.D., and colleagues at The University of Texas M. D. Anderson Cancer Center helped uncover a surprising and pivotal third path launched by a new cell.
Brief stress management sessions prior to and immediately after surgery may have both short- and long-term benefit for men undergoing a radical prostatectomy for early-stage prostate cancer, according to research from The University of Texas M. D. Anderson Cancer Center.
Scientists at The University of Texas M. D. Anderson Cancer Center have discovered a gene that protects PTEN, a major tumor-suppressor that is reduced but rarely mutated in about half of all breast cancers.
Does race and ethnicity affect cancer risk? This is the question frequently asked throughout the year and especially during National Minority Cancer Awareness Week, April 19 to 25. Each year, cancer statistics show that minority groups are more likely than the general population to develop and/or die from certain types of cancer.
A one-of-a-kind graduate program that focuses on the most lethal aspect of cancer will open this fall at The University of Texas M. D. Anderson Cancer Center with support from a highly competitive grant from The University of Texas System.
Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the American Association for Cancer Research (AACR), today received the inaugural Margaret Kripke Legend Award from The University of Texas M. D. Anderson Cancer Center.
Breast cancer patients with lymphedema in their upper arm experienced reduced fluid in the swollen arm by up to 39 percent after undergoing a super-microsurgical technique known as lymphaticovenular bypass, report researchers at The University of Texas M. D. Anderson Cancer Center.
Just more than one year after it was created, the office of Women Faculty Programs at The University of Texas M. D. Anderson Cancer Center has introduced a collection of essays by leading women faculty aimed at inspiring generations of women scientists to come.
Since its launch in 16 states this past November, The University of Texas M. D. Anderson Cancer Center has graduated 250 students and enrolled another 1,707 via its ASPIRE anti-tobacco program deployed in school districts across the country.
The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer. The approval is based on clinical studies led by researchers at The University of Texas M. D. Anderson Cancer Center and a national co-operative group.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right